![]() |
|
|
Vol. 30, Issue 6, 626-630, June 2002
Unité Mixte de Recherche, Institut National de La Recherche
Agronomique de Physiopathologie et Toxicologie Expérimentales,
Ecole Nationale Vétérinaire de Toulouse, France (C.M.L.,
P.-L.T., A.B.-M.); and Institut National de la Recherche Agronomique,
Station de Pharmacologie et Toxicologie, France (M.A.)
The transepithelial intestinal elimination of ivermectin was
studied using the intestinal closed-loop model in the rat. The common
bile duct was cannulated, and duodenum, jejunum, and ileum were
isolated in situ with their intact blood supplies. Following administration of 100, 200, or 400 µg/kg b.wt. ivermectin via the
carotid artery, the elimination of parent ivermectin into the small
intestinal lumen over 90 min was approximately 5-fold higher than in
bile. The major amount of secreted ivermectin was recovered in the
jejunum, but the duodenum showed a higher intestinal elimination
capacity than the other intestinal segments with respect to the
intestinal length. Systemic coadministration of the P-glycoprotein blocker verapamil significantly reduced the elimination capacity of
jejunum by 50%, which resulted in a 30% decrease of ivermectin overall elimination by the small intestine. In contrast, verapamil did
not significantly affect ivermectin secretion in duodenum, ileum, or
bile in the same animals. Ivermectin small intestinal and biliary
clearances were estimated to account for 27 and 5.5% of the total drug
clearance, which was evaluated from a parallel in vivo experiment in
which rats were given 200 µg/kg b.wt. ivermectin intra-arterially. In
conclusion, intestinal secretion plays a greater role than
biliary secretion in the overall elimination of ivermectin in the rat,
providing major amounts of active drug to the intestinal lumen
and to feces. This is discussed in terms of therapeutic efficacy
against intestinal parasites in humans and animals and of ecotoxicity
resulting from the contamination of livestock dung with parent drug.
This article has been cited by other articles:
![]() |
M. Ballent, A. Lifschitz, G. Virkel, J. Sallovitz, and C. Lanusse MODULATION OF THE P-GLYCOPROTEIN-MEDIATED INTESTINAL SECRETION OF IVERMECTIN: IN VITRO AND IN VIVO ASSESSMENTS Drug Metab. Dispos., March 1, 2006; 34(3): 457 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Morck, H. Hakk, U. Orn, and E. K. Wehler DECABROMODIPHENYL ETHER IN THE RAT: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION Drug Metab. Dispos., July 1, 2003; 31(7): 900 - 907. [Abstract] [Full Text] [PDF] |
||||